FNFengnan Niu

Fengnan Niu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fengnan Niu has a total of 60 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaolei Zhu

    Department of Neurology, Nanjing Drum Tower Hospital, Clinical College of Nanjing University of Chinese Medicine, Nanjing, 210008, People’s Republic of China

    2 shared publications
  • Xue Zhang

    2 shared publications
  • Abdukahar Kiram

    Division of Spine Surgery, Department of Orthopedic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China

    1 shared publication
  • Andi Xu

    Department of Pathology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China

    1 shared publication
  • Biao Zhang

    Department of Pathology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China

    1 shared publication
  • Chao Hu

    Department of Pathology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China

    1 shared publication

Latest Publications

  • Open Access

    Clinicopathological analysis of two pedigrees with Li-Fraumeni syndrome and literature review

    by Jialu Su, Xiaomu Hu, Xiaojia Liu, Xue Zhang, Lu He, Qi Sun, Fanqing Meng, Fengnan Niu

  • Open Access

    Novel GLA variant in Fabry cardiomyopathy: evidence of pathogenicity and amenability to migalastat

    by Yingao Fan, Chenyu Cui, Xue Zhang, Chao Hu, Andi Xu, Lian Wang, Hui Li, Xiaolei Zhu, Fengnan Niu

    Background: Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by pathogenic variants in the GLA gene and commonly involves the heart. This study aimed to investigate the pathogenicity of a novel missense variant and its amenability to migalastat. Methods: A retrospective analysis was conducted on 28 patients with FD collected over the past 10 years. Pathogenicity was assessed within a family carrying a de novo GLA missense variant through myocardial histopathology, bioinformatic predictions, protein structural modelling and in vitro cellular assays. Results: In a cohort of 28 patients (15 males, 13 females), cardiac involvement was prevalent. We further reported a family with GLA c.227T>A (p.Met76Lys) variant. Myocardial biopsy showed cardiomyocyte hypertrophy with diffuse vacuolisation, interstitial fibrosis and microvascular dysfunction. Immunohistochemistry demonstrated markedly decreased expression of α-galactosidase A (α-Gal A) in vacuolated cardiomyocytes. Biochemical testing revealed low-to-normal α-Gal A enzymatic activity together with elevated plasma globotriaosylsphingosine (lyso-Gb3). Bioinformatic analyses suggested this variant was probably pathogenic by altering the three-dimensional structure of GLA protein. AC16 cardiomyocytes overexpressing wild-type and mutant GLA were constructed via lentiviral vectors. Immunofluorescence staining revealed that the intracellular localisation of the mutant protein remained unaltered, whereas α-Gal A enzyme activity was significantly reduced. Treatment with migalastat, a pharmacological chaperone for α-Gal A, partially restored the mutant α-Gal A enzymatic activity. Conclusions: This study identified GLA c.227T>A (p.Met76Lys) as a novel pathogenic variant that primarily causes cardiac dysfunction. Migalastat may represent a therapeutic option for this variant.

  • Open Access

    Multisystem clinicopathologic and genetic analysis of MELAS

    by Shuai Xu, Jialiu Jiang, Leilei Chang, Biao Zhang, Xiaolei Zhu, Fengnan Niu

    Background and objectives: Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) syndrome is a maternally inherited mitochondrial disorder that mostly affects the central nervous system and skeletal muscle. This study provides a comprehensive summary of the clinical symptoms, multisystemic pathogenesis, and genetic characteristics of MELAS syndrome. The aim was to improve comprehension of clinical practice and gain a deeper understanding of the latest pathophysiological theories. Methods: The present investigation involved a cohort of patients diagnosed with MELAS at Nanjing Drum Tower Hospital between January 2014 and December 2022. Multisystem symptoms, magnetic resonance imaging/spectroscopy (MRI/MRS), muscle biopsy, and mitochondrial DNA (mtDNA) data were summarized and subsequently analysed. Results: This retrospective study included a cohort of 29 MELAS patients who predominantly presented symptoms such as stroke-like episodes, proximal muscle weakness, and exercise intolerance. MRI scans revealed very small infarcts beneath the deep cortex during stroke-like episodes, indicating nonvascular brain damage. Pathology analyses of the brain also showed neuronal degeneration and glial cell proliferation in the cerebral parenchyma. Proton magnetic resonance spectroscopy (1H-MRS) analysis revealed an increase in the lactate peak and a reduction in the N-acetylaspartate (NAA) level. Similarly, the phosphorus magnetic resonance spectroscopy (31P-MRS) analysis revealed an abnormal ratio of inorganic phosphate (Pi) to phosphocreatine (PCr). Muscle biopsy revealed the presence of ragged red fibres (RRFs) and cytochrome c oxidase (COX) enzyme-defective cells. These abnormalities indicate structural abnormalities in the mitochondria and deficiencies in oxidative phosphorylation, respectively. In addition to the common m.3243A > G variant, other prevalent variants, including m.5628 T > C, m.6352-13952del, and a 9-bp small deletion combined with m.3243A > G, exist. Conclusions: MELAS is a rare mitochondrial syndrome characterized by clinical heterogeneity and genetic heteroplasmy. Abnormalities in mitochondrial metabolic function and impairments in enzyme activity are the pathogenic processes underlying MELAS. Mitochondrial vasculopathy and mitochondrial neuropathy may provide a partial explanation for the unique aetiology of stroke-like episodes.


  • Open Access

    Ultrasound-assisted low-sodium salt curing to modify the quality characteristics of beef for aging

    by Lei Liu, Fengnan Niu, Yating Xiong, Peng Wang, Xiaoyu Lyu, Zongyun Yang


  • Muscle-bone cross-talk through the FNIP1-TFEB-IGF2 axis is associated with bone metabolism in human and mouse

    by Yan Mao, Zhen Jin, Jing Yang, Dengqiu Xu, Lei Zhao, Abdukahar Kiram, Yujing Yin, Danxia Zhou, Zongchao Sun, Liwei Xiao, et al.

    Clinical evidence indicates a close association between muscle dysfunction and bone loss; however, the underlying mechanisms remain unclear. Here, we report that muscle dysfunction–related bone loss in humans with limb-girdle muscular dystrophy is associated with decreased expression of folliculin-interacting protein 1 (FNIP1) in muscle tissue. Supporting this finding, murine gain- and loss-of-function genetic models demonstrated that muscle-specific ablation of FNIP1 caused decreased bone mass, increased osteoclastic activity, and mechanical impairment that could be rescued by myofiber-specific expression of FNIP1. Myofiber-specific FNIP1 deficiency stimulated expression of nuclear translocation of transcription factor EB, thereby activating transcription of insulin-like growth factor 2 ( Igf2 ) at a conserved promoter-binding site and subsequent IGF2 secretion. Muscle-derived IGF2 stimulated osteoclastogenesis through IGF2 receptor signaling. AAV9-mediated overexpression of IGF2 was sufficient to decrease bone volume and impair bone mechanical properties in mice. Further, we found that serum IGF2 concentration was negatively correlated with bone health in humans in the context of osteoporosis. Our findings elucidate a muscle-bone cross-talk mechanism bridging the gap between muscle dysfunction and bone loss. This cross-talk represents a potential target to treat musculoskeletal diseases and osteoporosis.


  • Open Access

    Development and validation of radiomics nomograms for preoperative prediction of characteristics in non-small cell lung cancer and circulating tumor cells

    by Yang Wang, Junkai Zhu, Xiaofan Lu, Wenxuan Cheng, Li Xu, Xin Wang, Jian Wang, Jun Yang, Fengnan Niu, Wenping Chen, et al.

    To develop and validate 3 radiomics nomograms for preoperative prediction of pathological and progression diagnosis in non-small cell lung cancer (NSCLC) as well as circulating tumor cells (CTCs). A total of 224 and 134 patients diagnosed with NSCLC were respectively gathered in 2018 and 2019 in this study. There were totally 1197 radiomics features that were extracted and quantified from the images produced by computed tomography. Then we selected the radiomics features with predictive value by least absolute shrinkage and selection operator and combined them into radiomics signature. Logistic regression models were built using radiomics signature as the only predictor, which were then converted to nomograms for individualized predictions. Finally, the performance of the nomograms was assessed on both cohorts. Additionally, immunohistochemical correlation analysis was also performed. As for discrimination, the area under the curve of pathological diagnosis nomogram and progression diagnosis nomogram in NSCLC were both higher than 90% in the training cohort and higher than 80% in the validation cohort. The performance of the CTC-diagnosis nomogram was somehow unexpected where the area under the curve were range from 60% to 70% in both cohorts. As for calibration, nonsignificant statistics (P > .05) yielded by Hosmer–Lemeshow tests suggested no departure between model prediction and perfect fit. Additionally, decision curve analyses demonstrated the clinically usefulness of the nomograms. We developed radiomics-based nomograms for pathological, progression and CTC diagnosis prediction in NSCLC respectively. Nomograms for pathological and progression diagnosis were demonstrated well-performed to facilitate the individualized preoperative prediction, while the nomogram for CTC-diagnosis prediction needed improvement.